Literature DB >> 22245106

Determination of ganciclovir in human plasma by ultra performance liquid chromatography-UV detection.

A Padullés1, H Colom, Y Armendariz, G Cerezo, A Caldes, L Pou, J Torras, J M Grinyó, N Lloberas.   

Abstract

OBJECTIVES: Implement a sensitive UHPLC method for the assay of ganciclovir in human plasma. DESIGN AND METHODS: We developed and validated a chromatographic method coupled to ultraviolet detection for quantification of ganciclovir, with a short run time using a small volume of human plasma. Comparison of system performance was made with respect to analysis time, efficiency and sensitivity.
RESULTS: Correlation coefficients (r) of the calibration curves ranged from 0.999744 to 0.999784. Within-day and between-day imprecision and inaccuracy, specificity and recovery were also evaluated for validation. The method was precise and accurate and the retention time was 0.7 min. The calibration curves were linear between 0.5 and 30 μg/mL. There was a good correlation between HPLC and UHPLC techniques.
CONCLUSIONS: We developed a method that is currently applied in a clinical study assessing GCV plasma concentration variability after ganciclovir and valganciclovir administration.
Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245106     DOI: 10.1016/j.clinbiochem.2011.12.014

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  5 in total

1.  Enhanced Oral Bioavailability of Epalrestat SBE7-β-CD Complex Loaded Chitosan Nanoparticles: Preparation, Characterization and in-vivo Pharmacokinetic Evaluation.

Authors:  Zunaira Alvi; Muhammad Akhtar; Arshad Mahmood; Nisar Ur-Rahman; Imran Nazir; Hadia Sadaquat; Muhammad Ijaz; Shahzada Khurram Syed; Muhammad Khurram Waqas; Yi Wang
Journal:  Int J Nanomedicine       Date:  2021-12-29

2.  Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.

Authors:  A Padullés; H Colom; O Bestard; E Melilli; N Sabé; R Rigo; J Niubó; J Torras; L Lladó; N Manito; A Caldés; J M Cruzado; J M Grinyó; N Lloberas
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

3.  Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections.

Authors:  Mutlaq M Al-Subaie; Khaled M Hosny; Khalid Mohamed El-Say; Tarek A Ahmed; Bader M Aljaeid
Journal:  Int J Nanomedicine       Date:  2015-06-15

4.  Valganciclovir-Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship.

Authors:  Alicia Galar; Maricela Valerio; Pilar Catalán; Xandra García-González; Almudena Burillo; Ana Fernández-Cruz; Eduardo Zataráin; Iago Sousa-Casasnovas; Fernando Anaya; María Luisa Rodríguez-Ferrero; Patricia Muñoz; Emilio Bouza
Journal:  Antibiotics (Basel)       Date:  2021-01-15

Review 5.  Therapeutic Drug Monitoring of Ganciclovir: Where Are We?

Authors:  Anne-Grete Märtson; Angela E Edwina; Hannah Yejin Kim; Marjolein Knoester; Daan J Touw; Marieke G G Sturkenboom; Jan-Willem C Alffenaar
Journal:  Ther Drug Monit       Date:  2022-02-01       Impact factor: 3.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.